X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare J.B.Chemicals with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

J.B.CHEMICALS vs FRESENIUS KABI ONCO. - Comparison Results

J.B.CHEMICALS    Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    J.B.CHEMICALS FRESENIUS KABI ONCO. J.B.CHEMICALS/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 17.7 22.1 80.0% View Chart
P/BV x 2.2 3.1 71.8% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 J.B.CHEMICALS   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    J.B.CHEMICALS
Mar-18
FRESENIUS KABI ONCO.
Mar-13
J.B.CHEMICALS/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs363176 206.3%   
Low Rs25579 324.8%   
Sales per share (Unadj.) Rs169.137.7 448.8%  
Earnings per share (Unadj.) Rs16.65.1 325.9%  
Cash flow per share (Unadj.) Rs23.46.7 348.3%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs172.542.5 405.5%  
Shares outstanding (eoy) m83.57158.23 52.8%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x1.83.4 54.1%   
Avg P/E ratio x18.625.0 74.5%  
P/CF ratio (eoy) x13.218.9 69.7%  
Price / Book Value ratio x1.83.0 59.9%  
Dividend payout %12.00-   
Avg Mkt Cap Rs m25,82720,135 128.3%   
No. of employees `0003.81.2 327.4%   
Total wages/salary Rs m2,511703 357.1%   
Avg. sales/employee Rs Th3,747.45,176.2 72.4%   
Avg. wages/employee Rs Th665.7610.4 109.1%   
Avg. net profit/employee Rs Th367.8699.6 52.6%   
INCOME DATA
Net Sales Rs m14,1355,963 237.0%  
Other income Rs m36618 2,032.2%   
Total revenues Rs m14,5015,981 242.4%   
Gross profit Rs m2,1781,430 152.3%  
Depreciation Rs m570258 220.9%   
Interest Rs m35-26 -134.2%   
Profit before tax Rs m1,9401,216 159.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m552342 161.4%   
Profit after tax Rs m1,387806 172.1%  
Gross profit margin %15.424.0 64.3%  
Effective tax rate %28.528.1 101.2%   
Net profit margin %9.813.5 72.6%  
BALANCE SHEET DATA
Current assets Rs m10,4705,102 205.2%   
Current liabilities Rs m2,7492,385 115.2%   
Net working cap to sales %54.645.6 119.9%  
Current ratio x3.82.1 178.1%  
Inventory Days Days55150 36.8%  
Debtors Days Days78113 68.5%  
Net fixed assets Rs m5,8115,148 112.9%   
Share capital Rs m167158 105.6%   
"Free" reserves Rs m14,2486,556 217.3%   
Net worth Rs m14,4166,732 214.1%   
Long term debt Rs m0952 0.0%   
Total assets Rs m17,64910,388 169.9%  
Interest coverage x56.6-45.8 -123.6%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.80.6 139.5%   
Return on assets %8.17.5 107.3%  
Return on equity %9.612.0 80.4%  
Return on capital %13.714.6 93.8%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m6,1645,298 116.4%   
Fx outflow Rs m1,3341,772 75.3%   
Net fx Rs m4,8293,525 137.0%   
CASH FLOW
From Operations Rs m1,2311,274 96.6%  
From Investments Rs m-208-1,204 17.3%  
From Financial Activity Rs m-595-196 303.5%  
Net Cashflow Rs m427-126 -338.2%  

Share Holding

Indian Promoters % 55.4 0.0 -  
Foreign collaborators % 0.3 81.0 0.4%  
Indian inst/Mut Fund % 3.4 0.3 1,130.0%  
FIIs % 3.9 9.6 40.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 37.0 9.1 406.6%  
Shareholders   30,437 42,599 71.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare J.B.CHEMICALS With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  SUVEN LIFESCIENCES  WYETH LTD  

Compare J.B.CHEMICALS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 66 Points Higher; Realty and Consumer Durable Stocks Witness Buying(Closing)

Indian share markets continued to witness volatility during closing hours and ended their day on a flat note.

Related Views on News

J.B.CHEMICALS Announces Quarterly Results (4QFY19); Net Profit Up 91.2% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, J.B.CHEMICALS has posted a net profit of Rs 422 m (up 91.2% YoY). Sales on the other hand came in at Rs 4 bn (up 18.9% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

J.B.CHEMICALS 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of J.B.CHEMICALS for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of J.B.CHEMICALS. Also includes updates on the valuation of J.B.CHEMICALS.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

J.B.CHEMICALS SHARE PRICE


Jun 19, 2019 (Close)

TRACK J.B.CHEMICALS

  • Track your investment in J.B.CHEMICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

J.B.CHEMICALS - STERLING BIOTECH COMPARISON

COMPARE J.B.CHEMICALS WITH

MARKET STATS